<DOC>
	<DOCNO>NCT02962661</DOCNO>
	<brief_summary>The goal clinical research study learn add mesenchymal stem cell ( MSCs ) standard care drug help control heart failure may cause anthracyclines . The safety MSCs also study . MSCs type stem cell remove bone marrow grow many different cell type use treat cancer disease , heart failure . The MSCs use study collect healthy donor store grown lab MD Anderson .</brief_summary>
	<brief_title>Trial With Mesenchymal Stromal Cells ( MSCs ) v Standard Care Cardiomyopathy</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( roll dice ) 1 3 study group . This do one know one study group well , , bad group . - If Group 1 , receive MSCs vein standard care drug heart failure MD Anderson . - If Group 2 , receive MSCs inject heart Baylor St. Luke 's Medical Center ( BSLMC ) standard care drug heart failure MD Anderson . You additional screen visit 1 week procedure . At visit sign additional consent form screen procedure visit BSLMC . - If Group 3 , receive standard care drug heart failure . You equal chance assign group . Study Drug Administration : If Group 1 , receive MSCs vein 10-20 minute 1 time week 4 week outpatient clinic MD Anderson . You remain clinic 6 hour MSC infusion study staff may check side effect . You also receive standard care drug heart failure . The study doctor tell drug take , risk , take . If Group 2 , sign separate consent form BSLMC . You may additional screening test and/or screen test repeat . This explain . You procedure doctor insert long , narrow tube , call catheter , blood vessel , usually leg , guide catheter heart help special x-ray machine . X-ray dye inject catheter x-ray machine take pictures/video heart . This procedure call cardiac catheterization/left heart ventricular angiography . The doctor use special device , call NOGA , monitor heart function . This procedure , refer NOGA mapping , help doctor find part heart muscle still healthy receive enough blood oxygen part likely respond MSC injection . This help doctor decide inject MSCs . Your doctor use special catheter retractable needle inject study product damage area heart muscle . This catheter investigational approve FDA . There 15 injection small amount ( drop ) fluid contain million cell heart muscle . Following procedure , watch overnight . If Group 3 , receive standard care drug heart failure . The study doctor tell drug take , risk , take . Study Visits : On Days 1 , 14 , 21 , 28 ( +/- 5 day ) , Group 1 3 : - Blood ( 4 tablespoon ) draw routine test check heart liver function . - On Day 28 , ECHO . If Group 2 , day procedure : - Blood ( 4 tablespoon ) draw routine test check heart liver function . - You 3 EKGs row ECHO . One ( 1 ) time month Months 1-6 , participant : - Blood ( 4 tablespoon ) draw routine test check heart liver function . At Months 3 6 , blood also use biomarker test . - You follow-up visit cardiologist . If Group 3 , follow-up visit cardiologist one ( 1 ) time month Months 2-6 . - You follow-up visit transplant doctor . If Group 3 , follow-up visit transplant doctor one ( 1 ) time month Months 2-6 . - At Months 3 6 , EKG ECHO . - At Months 3 6 , perform physical test , include walk 6 minute . At Month 12 : - You follow-up visit transplant doctor . - You follow-up visit cardiologist . - You EKG ECHO . Length Study : If Group 1 , able receive 4 infusion MSCs . If Group 2 , receive 15 injection MSCs procedure.You longer able receive MSCs disease get bad , intolerable side effect occur , unable follow study direction . If Group 3 , length treatment depend standard care therapy chosen . Your participation study Month 12 . This investigational study . MSCs FDA-approved commercially available . They use research purpose . The study doctor explain design work . Up 72 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>1 . Patients LVEF &lt; /= 40 % document treatment anthracyclines malignancy dose without evidence cause cardiomyopathy . 2 . Age &gt; /= 18 &lt; /= 80 year Age . 3 . Documented NYHA class I , II III . 4 . Patients persistent LV dysfunction 90 day discontinuation trastuzumab . 5 . No evidence ischemic heart disease base 2013 ACC/AHA guideline . 6 . Been treated appropriate maximal medical therapy heart failure . 7 . Patient legally authorize representative able sign inform consent . 1 . Evidence Ischemic Heart Disease determine study cardiologist . 2 . Significant Valvular Disease . ( AS AVA &lt; 1.5 severe AR MR ) . 3 . History Familial Cardiomyopathy . 4 . Documented myocarditis within 2 month enrollment . 5 . History Infiltrative cardiomyopathy restrictive cardiomyopathy . 6 . Presence leave ventricular thrombus document echocardiography leave ventriculogram . 7 . Creatinine clearance &lt; 50ml/min . 8 . Liver function test &gt; 3 x upper limit normal . 9 . Inotropic dependence . 10 . Unstable lifethreatening arrhythmia . 11 . Autoimmune disorder current immunosuppressive therapy . 12 . Uncontrolled infection respond appropriate antimicrobial treatment 7 day . Study Chair final arbiter . 13 . Mechanical Bioprosthetic heart valve . 14 . Trastuzumab treatment within last 3 month . 15 . Automatic implantable cardioverter defibrillator ( AICD ) placement within last 30 day . 16 . AICD fire within last 30 day . 17 . Pregnant breastfeeding female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Other form heart disease</keyword>
	<keyword>Left ventricular dysfunction</keyword>
	<keyword>LV</keyword>
	<keyword>Heart failure secondary chemotherapy anthracyclines</keyword>
	<keyword>Human mesenchymal stem cell</keyword>
	<keyword>hMSCs</keyword>
	<keyword>Mesenchymal Stromal Cells</keyword>
	<keyword>MSCs</keyword>
	<keyword>Intravenous infusion</keyword>
	<keyword>Transendocardial injection</keyword>
	<keyword>Standard care drug heart failure</keyword>
</DOC>